Summary
The Maharashtra FDA, led by Tukaram Mundhe, canceled a Cipla unit's drug license for Reactin Plus due to irregularities found during a June inspection, specifically an unauthorized claim on its packaging.
Maharashtra FDA Cancels Cipla Unit's Drug Licence for Reactin Plus Irregularities
HyperFast News
Related news
Maharashtra FDA withdraws Cipla Pharma license cancellation order after Bombay HC criticism
15 Sept 2026, 5:05 am · News
Cipla Gets U.S. FDA Approval for Generic Asthma, COPD Drug
15 Sept 2026, 5:05 am · News
Cipla Expects US Sales Ramp-Up by FY27, Maintains Full-Year Guidance
15 Sept 2026, 5:05 am · News
